E. Les and . Dans, étaient représentés par l'hypotension (24,8%) et les vomissements (6,5%)

U. Arrêt-de-traitement-définitif-en-raison, 4%) patients selon les études) ; les taux d'arrêt dans notre travail sont plus faibles puisque la situation se, 5%) à quatre

A. Chevallier, Prise en charge de l???art??riopathie chronique oblit??rante ath??roscl??reuse des membres inf??rieurs, Journal des Maladies Vasculaires, vol.31, issue.4, pp.206-223, 2006.
DOI : 10.1016/S0398-0499(06)76545-3

A. Hirsch, M. Criqui, D. Treat-jacobson, J. Regensteiner, M. Creager et al., Peripheral Arterial Disease Detection, Awareness, and Treatment in Primary Care, JAMA, vol.286, issue.11, pp.1317-1324, 2001.
DOI : 10.1001/jama.286.11.1317

W. Meijer, D. Grobbee, M. Hunink, A. Hofman, and A. Hoes, Determinants of Peripheral Arterial Disease in the Elderly, Archives of Internal Medicine, vol.160, issue.19, pp.2934-2938, 2000.
DOI : 10.1001/archinte.160.19.2934

C. Diehm, A. Schuster, J. Allenberg, H. Darius, R. Haberl et al., High prevalence of peripheral arterial disease and co-morbidity in 6880 primary care patients: cross-sectional study, Atherosclerosis, vol.172, issue.1, pp.95-105, 2004.
DOI : 10.1016/S0021-9150(03)00204-1

H. Boccalon, P. Lehert, and M. Mosnier, Assessment of the prevalence of atherosclerotic lower limb arteriopathy in France as a systolic index in a vascular risk population], J Mal Vasc. févr, vol.25, issue.1, pp.38-46, 2000.

J. Letouzey, A. Genet, R. Amoretti, . Sanesco, and . Cardiologie, Livre blanc sur la prise en charge des maladies cardiovasculaires en France, 2000.

M. Tendera, V. Aboyans, M. Bartelink, and I. Baumgartner, ESC Guidelines on the Diagnosis and Treatment of Peripheral Artery Diseases, Endorsed by: the European Stroke Organisation, pp.2851-2906, 2011.
DOI : 10.1016/j.rec.2011.11.007

URL : https://hal.archives-ouvertes.fr/hal-00678704

L. Norgren, W. Hiatt, J. Dormandy, M. Nehler, K. Harris et al., Inter-Society Consensus for the Management of Peripheral Arterial Disease (TASC II), Journal of Vascular Surgery, vol.45, issue.1, pp.5-67, 2007.
DOI : 10.1016/j.jvs.2006.12.037

P. Greenland, J. Alpert, G. Beller, E. Benjamin, M. Budoff et al., 2010 ACCF/AHA Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults, Journal of the American College of Cardiology, vol.56, issue.25, pp.50-103, 2010.
DOI : 10.1016/j.jacc.2010.09.001

C. Diehm, S. Lange, H. Darius, D. Pittrow, V. Stritzky et al., Association of low ankle brachial index with high mortality in primary care, European Heart Journal, vol.27, issue.14, pp.1743-1749, 2006.
DOI : 10.1093/eurheartj/ehl092

D. Bhatt, P. Steg, E. Ohman, A. Hirsch, Y. Ikeda et al., International Prevalence, Recognition, and Treatment of Cardiovascular Risk Factors in Outpatients With Atherothrombosis, JAMA, vol.295, issue.2
DOI : 10.1001/jama.295.2.180

S. Meves, C. Diehm, K. Berger, D. Pittrow, H. Trampisch et al., Peripheral Arterial Disease as an Independent Predictor for Excess Stroke Morbidity and Mortality in Primary-Care Patients: 5-Year Results of the getABI Study, Cerebrovascular Diseases, vol.29, issue.6, pp.546-554, 2010.
DOI : 10.1159/000306640

H. Feringa, J. Bax, V. Van-waning, E. Boersma, A. Elhendy et al., The Long-term Prognostic Value of the Resting and Postexercise Ankle-Brachial Index, Archives of Internal Medicine, vol.166, issue.5, pp.529-535, 2006.
DOI : 10.1001/archinte.166.5.529

P. Mehler, J. Coll, R. Estacio, A. Esler, R. Schrier et al., Intensive Blood Pressure Control Reduces the Risk of Cardiovascular Events in Patients With Peripheral Arterial Disease and Type 2 Diabetes, Circulation, vol.107, issue.5, pp.753-756, 2003.
DOI : 10.1161/01.CIR.0000049640.46039.52

F. Becker, H. Robert-ebadi, J. Ricco, C. Setacci, P. Cao et al., Chapter I: Definitions, Epidemiology, Clinical Presentation and Prognosis, European Journal of Vascular and Endovascular Surgery, vol.42, issue.2, pp.4-12, 2011.
DOI : 10.1016/S1078-5884(11)60009-9

URL : http://doi.org/10.1016/s1078-5884(11)60009-9

F. Becker, F. Luizy, J. Baud, O. Pichot, and S. , Standards de qualit?? pour la pratique des examens Doppler et ??cho-Doppler art??riel des membres inf??rieurs en m??decine vasculaire. Rapport de la Soci??t?? fran??aise de m??decine vasculaire (SFMV), Journal des Maladies Vasculaires, vol.36, issue.6, pp.364-385, 2011.
DOI : 10.1016/j.jmv.2011.10.002

A. Hirsch, Z. Haskal, N. Hertzer, C. Bakal, M. Creager et al., guidelines for the management of patients with peripheral arterial disease (lower extremity, renal, mesenteric, and abdominal aortic): executive summary a collaborative report from the American Association for Vascular Surgery/Society for Vascular Surgery, Society for Cardiovascular Angiography and Interventions, Society for Vascular Medicine and Biology, Society of Interventional Radiology, and the ACC/AHA Task Force on Practice Guidelines (Writing Committee to Develop Guidelines for the Management of Patients With Peripheral Arterial Disease) endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation Institute; Society for Vascular Nursing; TransAtlantic Inter-Society Consensus; and Vascular Disease Foundation, National Heart, Lung, and Blood J Am Coll Cardiol, vol.2147, issue.6, pp.1239-1312, 2005.

V. Aboyans, M. Criqui, P. Abraham, M. Allison, M. Creager et al., Measurement and Interpretation of the Ankle-Brachial Index: A Scientific Statement From the American Heart Association, Circulation, vol.126, issue.24, pp.2890-2909, 2012.
DOI : 10.1161/CIR.0b013e318276fbcb

URL : https://hal.archives-ouvertes.fr/hal-00921590

W. Group, . Writing, A. /. Members, . Task, and . Members, 2011 ACCF/AHA Focused Update of the Guideline for the Management of patients with peripheral artery disease (Updating the 2005 Guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on practice guidelines, Circulation. 1 nov, vol.124, issue.18, pp.2020-2045, 2005.

C. Steering and C. , A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE), CAPRIE Steering Committee. Lancet. 16 nov, vol.348, issue.9038, pp.1329-1339, 1996.

L. Norgren, A. Alwmark, K. Angqvist, B. Hedberg, D. Bergqvist et al., A stable prostacyclin analogue (Iloprost) in the treatment of ischaemic ulcers of the lower limb, European Journal of Vascular Surgery, vol.4, issue.5, pp.463-467, 1990.
DOI : 10.1016/S0950-821X(05)80784-4

F. Brock, O. Abri, G. Baitsch, G. Bechara, K. Beck et al., Iloprost in the treatment of ischemic tissue lesions in diabetics. Results of a placebo-controlled multicenter study with a stable prostacyclin derivative], Schweiz Med Wochenschr. 6 oct, vol.120, issue.40, pp.1477-1482, 1990.

C. Diehm, O. Abri, G. Baitsch, G. Bechara, K. Beck et al., Iloprost, ein stabiles Prostacyclinderivat, bei arterieller Verschlu??krankheit im Stadium IV: Eine placebo-kontrollierte Multizenterstudie, DMW - Deutsche Medizinische Wochenschrift, vol.114, issue.20, pp.783-788, 1946.
DOI : 10.1055/s-2008-1066673

K. Balzer, G. Bechara, H. Bisler, H. Clevert, C. Diehm et al., Reduction of ischaemic rest pain in advanced peripheral arterial occlusive disease. A double blind placebo controlled trial with iloprost, Int Angiol J Int Union Angiol. déc, vol.10, issue.4, pp.229-232, 1991.

J. Olin, Thromboangiitis Obliterans (Buerger's Disease), New England Journal of Medicine, vol.343, issue.12, pp.864-869, 2000.
DOI : 10.1056/NEJM200009213431207

X. Puéchal and J. Fiessinger, Thromboangiitis obliterans or Buerger's disease: challenges for the rheumatologist, Rheumatology, vol.46, issue.2, pp.192-199, 2007.
DOI : 10.1093/rheumatology/kel388

J. Reny and J. Cabane, Buerger's disease or thromboangiitis obliterans]. Rev Médecine Interne Fondée Par Société Natl Francaise Médecine Interne, janv, vol.19, issue.1, pp.34-43, 1998.

L. Cooper, T. Tse, M. Mikhail, R. Mcbane, A. Stanson et al., Long-term survival and amputation risk in thromboangiitis obliterans (Buerger's disease), Journal of the American College of Cardiology, vol.44, issue.12, pp.2410-2411, 2004.
DOI : 10.1016/j.jacc.2004.09.029

R. Ma?ecki, K. Zdrojowy, and R. Adamiec, Thromboangiitis obliterans in the 21st century???A new face of disease, Atherosclerosis, vol.206, issue.2, pp.328-334, 2009.
DOI : 10.1016/j.atherosclerosis.2009.01.042

J. Olin, J. Young, R. Graor, W. Ruschhaupt, and J. Bartholomew, The changing clinical spectrum of thromboangiitis obliterans (Buerger's disease), Circulation. nov, vol.82, issue.5, 1990.

J. Olin and A. Shih, Thromboangiitis obliterans (Buerger??s disease), Current Opinion in Rheumatology, vol.18, issue.1, pp.18-24, 2006.
DOI : 10.1097/01.bor.0000198000.58073.aa

F. Avcu, E. Akar, U. Demirkiliç, E. Yilmaz, N. Akar et al., The Role of Prothrombotic Mutations in Patients with Buerger's Disease, Thrombosis Research, vol.100, issue.3, pp.143-147, 2000.
DOI : 10.1016/S0049-3848(00)00310-8

M. Brodmann, W. Renner, G. Stark, M. Winkler, E. Pabst et al., Prothrombotic Risk Factors in Patients with Thrombangitis Obliterans, Thrombosis Research, vol.99, issue.5, pp.483-486, 2000.
DOI : 10.1016/S0049-3848(00)00266-8

E. Joviliano, R. Dellalibera-joviliano, M. Dalio, P. Évora, and C. Piccinato, Etiopathogenesis, clinical diagnosis and treatment of thromboangiitis obliterans ??? current practices, International Journal of Angiology, vol.18, issue.03, p.119, 2009.
DOI : 10.1055/s-0031-1278337

A. Bozkurt, C. Köksal, M. Demirbas, A. Erdo?an, A. Rahman et al., A randomized trial of intravenous iloprost (a stable prostacyclin analogue) versus lumbar sympathectomy in the management of Buerger's disease, Int Angiol J Int Union Angiol. juin, vol.25, issue.2, pp.162-168, 2006.

J. Fiessinger and M. Schäfer, Trial of iloprost versus aspirin treatment for critical limb ischaemia of thromboangiitis obliterans, The Lancet, vol.335, issue.8689, pp.555-557, 1990.
DOI : 10.1016/0140-6736(90)90346-7

A. Bozkurt, K. Cengiz, A. Caner, D. Mine, S. Oner et al., A Stable Prostacyclin Analogue (Iloprost) in the Treatment of Buerger's Disease: A Prospective Analysis, p.150

. Patients, Ann Thorac Cardiovasc Surg Off J Assoc Thorac Cardiovasc Surg Asia, 2012.

J. Korn, M. Mayes, M. Cerinic, M. Rainisio, M. Pope et al., Digital ulcers in systemic sclerosis: Prevention by treatment with bosentan, an oral endothelin receptor antagonist, Arthritis & Rheumatism, vol.132, issue.12, pp.3985-3993, 2004.
DOI : 10.1002/art.20676

M. Matucci-cerinic, C. Denton, D. Furst, M. Mayes, V. Hsu et al., Bosentan treatment of digital ulcers related to systemic sclerosis: results from the RAPIDS-2 randomised, double-blind, placebo-controlled trial, Annals of the Rheumatic Diseases, vol.70, issue.1, pp.32-38, 2011.
DOI : 10.1136/ard.2010.130658

D. Haro, J. Acin, F. Bleda, S. Varela, C. Esparza et al., Treatment of thromboangiitis obliterans (Buerger's disease) with bosentan, BMC Cardiovascular Disorders, vol.61, issue.12, p.5, 2012.
DOI : 10.1002/art.22634

E. Leroy, C. Black, R. Fleischmajer, S. Jablonska, T. Krieg et al., Scleroderma (systemic sclerosis): classification, subsets and pathogenesis, J Rheumatol. févr, vol.15, issue.2, pp.202-205, 1988.

H. Poormoghim, M. Lucas, N. Fertig, T. Medsger, and . Jr, Systemic sclerosis sine scleroderma: Demographic, clinical, and serologic features and survival in forty-eight patients, Arthritis & Rheumatism, vol.43, issue.2, pp.444-451, 2000.
DOI : 10.1002/1529-0131(200002)43:2<444::AID-ANR27>3.0.CO;2-G

E. Leroy, T. Medsger, and . Jr, Criteria for the classification of early systemic sclerosis, J Rheumatol. juill, vol.28, issue.7, pp.1573-1576, 2001.

C. Francès, Y. Allanore, J. Cabane, P. Carpentier, C. Dumontier et al., Management of digital ulcers from systemic scleroderma]. Presse Médicale Paris Fr 1983, févr, vol.37, issue.2 2, pp.271-285, 2008.

F. Wigley, R. Wise, J. Seibold, D. Mccloskey, G. Kujala et al., Intravenous Iloprost Infusion in Patients with Raynaud Phenomenon Secondary to Systemic Sclerosis: A Multicenter, Placebo-controlled, Double-Blind Study, Annals of Internal Medicine, vol.120, issue.3, pp.199-206, 1994.
DOI : 10.7326/0003-4819-120-3-199402010-00004

T. Tingey, J. Shu, J. Smuczek, and J. Pope, Meta-Analysis of Healing and Prevention of Digital Ulcers in Systemic Sclerosis, Arthritis Care & Research, vol.7, issue.Suppl, pp.1460-1471, 2013.
DOI : 10.1002/acr.22018

M. Hildebrand, Pharmacokinetics and tolerability of oral iloprost in thromboangiitis obliterans patients, European Journal of Clinical Pharmacology, vol.53, issue.1, pp.51-56, 1997.
DOI : 10.1007/s002280050336

Y. Benhamou, V. Vandecandelaere, R. Varin, L. Besnerais, M. Cailleux et al., Administration d???iloprost au sein d???une cohorte de 30??patients atteints d???isch??mie digitale??: d??termination de crit??res de bonne tol??rance clinique, La Revue de M??decine Interne, vol.31, p.78, 2010.
DOI : 10.1016/j.revmed.2010.03.443

C. Kuhar, T. Mesti, and B. Zakotnik, Digital ischemic events related to gemcitabine: Report of two cases and a systematic review, Radiology and Oncology, vol.44, issue.4, pp.257-261, 2010.
DOI : 10.2478/v10019-010-0020-1

P. Gouny, J. Gaitz, and M. Vayssairat, Acute Hand Ischemia Secondary to Intraarterial Buprenorphine Injection: Treatment with Iloprost and Dextran-40: A Case Report, Angiology, vol.50, issue.7, pp.605-606, 1999.
DOI : 10.1177/000331979905000711

C. Assie and M. I. , Atteintes artérielles des membres supérieurs et inférieurs au cours de la maladie de Horton. Presse Médicale, févr, vol.40, issue.2, pp.151-161, 2011.
DOI : 10.1016/j.lpm.2010.11.005

L. Gullo, R. , D. Filippis, L. Caliri, A. Bagnato et al., Successful treatment of necrotizing vasculitic lesions after infusion of iloprost in a patient with cryoglobulinemia and chronic HCV infection, Clin Exp Rheumatol. déc, vol.23, issue.6, pp.912-913, 2005.

L. Teixeira, A. Servettaz, M. Mehrenberger, L. Noël, L. Guillevin et al., Crise r??nale scl??rodermique, La Presse M??dicale, vol.35, issue.12, pp.1966-74, 2006.
DOI : 10.1016/S0755-4982(06)74931-4

D. Metz, N. 'guyen, P. Chapoutot, L. Graciet, J. Taupin et al., Massive pulmonary embolism disclosing thrombocytopenia induced by low molecular weight heparin. Therapeutic success of prostacyclin], Ann Cardiol Angéiologie. déc, vol.40, issue.10, pp.619-621, 1991.

G. Palatianos, C. Foroulis, M. Vassili, P. Matsouka, G. Astras et al., Preoperative detection and management of immune heparin-induced thrombocytopenia in patients undergoing heart surgery with iloprost, The Journal of Thoracic and Cardiovascular Surgery, vol.127, issue.2, pp.548-554, 2004.
DOI : 10.1016/j.jtcvs.2003.08.042

D. Montani, O. Sitbon, X. Jaïs, S. Cabrol, G. Simonneau et al., [Treatment of pulmonary arterial hypertension]. Presse Médicale Paris Fr 1983, pp.1445-1455, 2005.
URL : https://hal.archives-ouvertes.fr/hal-01455600

M. Samson, N. Falvo, S. Audia, V. Leguy, S. Berthier et al., Attention aux spasmes et thromboses sous iloprost, La Revue de M??decine Interne, vol.29, pp.397-398, 2008.
DOI : 10.1016/j.revmed.2008.10.297

E. Perrier, G. Quiniou, C. Godreuil, S. Geffroy, E. Naoum et al., Vasoplegic shock and myocardial infarction during administration of iloprost]. Presse Médicale Paris Fr 1983, 23 avr, vol.34, issue.8, pp.585-586, 2005.

M. Colaci, M. Sebastiani, D. Giuggioli, A. Manfredi, R. Rossi et al., Cardiovascular risk and prostanoids in systemic sclerosis, Clin Exp Rheumatol. avr, vol.26, issue.2, pp.333-336, 2008.

M. André, I. Delèvaux, J. Cabane, J. Piette, and O. Aumaître, Infacrtus du myocarde sous Iloprost dans la sclérodermie, Rev Med Interne. juin, vol.21, 2000.

L. Bettoni, A. Geri, P. Airò, E. Danieli, I. Cavazzana et al., Systemic Sclerosis Therapy with Iloprost: A Prospective Observational Study of 30 Patients Treated for a Median of 3 Years, Clinical Rheumatology, vol.21, issue.3, pp.244-250, 2002.
DOI : 10.1007/PL00011223

G. Thomas, S. Kadam, M. Mohammed, and B. Andrews, Compartment Syndrome as a Rare Complication of Iloprost Infusion for Peripheral Vascular Disease, Annals of Vascular Surgery, vol.25, issue.4, pp.555-566, 2011.
DOI : 10.1016/j.avsg.2010.11.012

C. Roome and J. Thompson, Pre-emptive metoclopramide and ondansetron for nausea and vomiting associated with iloprost infusions, Pharmacy World and Science, vol.23, issue.3, p.122, 2001.
DOI : 10.1023/A:1011231507085

L. Robertson and A. Andras, Prostanoids for intermittent claudication, Cochrane Database Syst Rev, vol.5, issue.4, p.986, 2013.
DOI : 10.1002/14651858.CD000986.pub3

H. Torley, R. Madhok, H. Capell, R. Brouwer, P. Maddison et al., A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases., Annals of the Rheumatic Diseases, vol.50, issue.11, pp.800-804, 1991.
DOI : 10.1136/ard.50.11.800

A. Kawald, G. Burmester, D. Huscher, C. Sunderkötter, and G. Riemekasten, Low versus high-dose iloprost therapy over 21 days in patients with secondary Raynaud's phenomenon and systemic sclerosis: a randomized, open, single-center study, J Rheumatol. sept, vol.35, issue.9, pp.1830-1837, 2008.

W. Beischer, J. Dembski, J. Gruss, F. Hofgärtner, A. Horsch et al., Low-dose iloprost infusions compared to the standard dose in patients with peripheral arterial occlusive disease Fontaine stage IV. DAWID Study Group, VASA Z Für Gefässkrankheiten. févr, vol.27, issue.1, pp.15-19, 1998.

M. Arreghini, P. Prudente, W. Maglione, C. Arnoldi, S. Tosi et al., Tolerability, safety and efficacy of Iloprost infusion without peristaltic pump in systemic sclerosis, Reumatismo, vol.53, issue.2, pp.140-144, 2001.
DOI : 10.4081/reumatismo.2001.140

P. Staben and M. Albring, Treatment of patients with peripheral arterial occlusive disease fontaine stage III and IV with intravenous iloprost: an open study in 900 patients, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol.54, issue.5, pp.327-333, 1996.
DOI : 10.1016/S0952-3278(96)90046-0

C. Rabl, S. , D. Rossa, A. Pepe, P. et al., Long-term cyclic intravenous iloprost in systemic sclerosis: clinical experience from a single center, Reumatismo, vol.64, issue.3, pp.158-165, 2012.

W. Krause and T. Krais, Pharmacokinetics and pharmacodynamics of the prostacyclin analogue iloprost in man, European Journal of Clinical Pharmacology, vol.13, issue.9, pp.61-68, 1986.
DOI : 10.1007/BF00614197

W. Krause and T. Krais, Pharmacokinetics and pharmacodynamics of radio-labeled iloprost in elderly volunteers, European Journal of Clinical Pharmacology, vol.225, issue.21, pp.597-605, 1987.
DOI : 10.1007/BF02455995

H. Zachariae, L. Halkier-sørensen, P. Bjerring, and L. Heickendorff, Treatment of ischaemic digital ulcers and prevention of gangrene with intravenous iloprost in systemic sclerosis, Acta Derm Venereol. mai, vol.76, issue.3, pp.236-238, 1996.

S. Schellong, E. Altmann, P. Von-bilderling, G. Rudofsky, P. Waldhausen et al., Microcirculation and tolerability following i.v. infusion of PGE1 and iloprost: a randomized cross-over study in patients with critical limb ischemia, Prostaglandins, Leukotrienes and Essential Fatty Acids, vol.70, issue.6, pp.503-509, 2004.
DOI : 10.1016/j.plefa.2003.10.006

D. Donato, G. Gussoni, G. De-donato, G. Andreozzi, G. Bonizzoni et al., The ILAILL Study: Iloprost as Adjuvant to Surgery for Acute Ischemia of Lower Limbs, Annals of Surgery, vol.244, issue.2, pp.185-193, 2006.
DOI : 10.1097/01.sla.0000217555.49001.ca

M. Creager, R. Pande, and W. Hiatt, A randomized trial of iloprost in patients with intermittent claudication, Vascular Medicine, vol.13, issue.1, pp.5-13, 2008.
DOI : 10.1177/1358863X07084910